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An 86-year-old male with history of metastatic prostate carcinoma and hypertension was
admitted due to acute onset dyspnea and lower extremity pain and swelling. Transthoracic
echocardiography revealed a large right atrial thrombus extending in to the right ventricle.
Within 12 h, the patient developed severe hypoxemia, tachypnea with sustained hypo-
tension and cardiogenic shock due to presumedmassive pulmonary embolism. The patient
underwent emergency pulmonary angiography which showed large emboli in the right
main pulmonary artery extending in to the middle and lower lobe branches. An ultrasonic-
accelerated thrombolytic catheter was placed in the right main pulmonary artery for
continuous infusion of alteplase for 20 h. Repeat pulmonary angiogram showed resolution
of the large pulmonary emboli, with normal flow in to the distal pulmonary arteries. Sig-
nificant improvement of hemodynamics, symptoms and hypoxemia occurred as well.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
Acute pulmonary embolism (PE) is the third most common
cause of death among hospitalized patients.1
Therapeutic escalation beyond anticoagulation with hepa-
rin is necessary and of extreme importance in acute massive
pulmonary embolism (MPE), defined by persistent systemic
hypotension and cardiogenic shock and hemodynamic(M. Porres-Aguilar).
2013, Cardiological Societinstability, aswell as in a highly selected group of patientswith
submassive PE, in which there is objective evidence of right
ventricular (RV) dysfunction by transthoracic echocardiogra-
phy (TTE) or computed tomographic angiography (CTA) of the
chest and elevated biomarkers of myocardial injury.2 In recent
years, the best current evidence suggests that pharmaco-
mechanical interventions represent a novel therapeutic mo-
dality for a variety of thromboembolic conditions, includingy of India. All rights reserved.
Fig. 1 e Transthoracic echocardiogram (TTE) showing large
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 6 9 9e7 0 2700peripheral occlusive arterial disease, ischemic stroke, and
venous thromboembolism (VTE) spectrum of disorders.3
Endovascular techniques for MPE may be indicated in
compromised patients who are unsuitable to receive systemic
thrombolysis due to high-risk of bleeding complications.
Ultrasonic-accelerated catheter-directed thrombolysis (UCDT)
works by displaying a high-frequency low intensity ultra-
sound waves in order to accelerate clot dissolution by disso-
ciating the fibrin strands, thereby reducing treatment time
and the incidence of systemic thrombolysis-related compli-
cations, especially hemorrhagic complications.4 In some
experienced centers, UCDT strategies are being advocated as a
replacement for systemic thrombolysis.
We present the case of a patient who was successfully
treated with UCDT strategy within few hours post-admission
to the hospital for further work-up of significant acute PE.right atrial thrombus.
Fig. 2 e a: Pulmonary angiogram demonstrating the right
mainpulmonary arterywith large extensive thromboemboli,
involving the right middle and lower lobar arterial branches.
b: Pulmonary angiogram showing patient right main
pulmonary artery with adequate distal filling of the entire
pulmonary vasculature after successful use of ultrasonic-
accelerated catheter-directed thrombolysis (UCDT).2. Case presentation
An 86-year-old male with history of metastatic prostate car-
cinoma and hypertension was admitted due to 4-day history
of left lower extremity swelling, severe pain and redness that
had been progressively worse.
Associated symptoms included a 3-day history of dyspnea,
progressivelyworse to the point to beworsened uponminimal
activities. He denied orthopnea, paroxysmal nocturnal dys-
pnea, recent surgeries, prolonged immobilization, fever,
chills, cough, hemoptysis or chest discomfort.
Physical examination revealed the following vital signs:
heart rate 87 beats/min, blood pressure of 111/79 mmHg,
24 respirations/min, and oxygen saturation (O2Sat) at 95% on
2 L by nasal cannula. Cardiovascular examination significant
for 2/6 systolic murmur in left mid sternal border, no gallops,
splits or rubs. He had 2þ pitting edema up to the upper third of
the left calf, no cyanosis; and calves nontender to palpation.
Remarkable laboratory findings included abnormal blood
urea nitrogen (BUN) of 47 mg/dl and creatinine of 1.8 mg/dl, as
well as elevated brain natriuretic peptide (BNP) of 999 pg/ml,
troponins, prothrombin time (PT), partial thromboplastin time
(PTT), and INR were within normal limits. Electrocardiogram
showed normal sinus rhythm without acute abnormalities
(e.g. sinus tachycardia, right axis deviation, T wave inversion
in precordial leads or indirect signs of RV dilatation/hyper-
trophy). Chest radiograph was unremarkable.
TTE was immediately obtained, revealing a large right
atrial thrombusmeasuring 2.7 1.4 cm, extending in to the RV
(Fig. 1). The patient was empirically placed in enoxaparin
1 mg/kg subcutaneously (SQ) adjusted for his creatinine
clearance every 12 h, however, within 12 h after admission to
our institution and while awaiting ventilation/perfusion (V/Q)
lung scan results, the patient developed severe hypoxemia (O2
needs significantly increased to 15 L while in face mask with
reservoir in order to keep O2Sats >92%), with sustained hy-
potension (75/45 mmHg) with cardiogenic shock due to pre-
sumed MPE. The patient underwent emergent pulmonary
angiography after briefly discussing that benefits will
outweigh the risks of such invasive procedure, being a life-
saving intervention. It showed large emboli in the main pul-
monary artery extending in to the right middle and lower lobebranches of the right main pulmonary artery (Fig. 2a). An ul-
trasonic endovascular system (EKOS Corporation, Bothell,
Washington) catheterwas placed in the rightmain pulmonary
artery for continuous infusion of recombinant tissue
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 6 9 9e7 0 2 701plasminogen activator (r-TPA) for 1 mg/h for 20 h. Repeat
pulmonary angiogram showed resolution ofMPE, with normal
flow in to the distal pulmonary arteries (Fig. 2b).
Significant clinical improvement, as well as pulmonary
hemodynamics, symptomatology and hypoxemia occurred as
well during the patient’s hospitalization, being discharge
home to hospice care given his advanced malignancy as well
as on life-long parenteral anticoagulation with enoxaparin SQ
every 12 h.3. Discussion
MPE, characterized by circulatory collapse and hemodynamic
instability, has been associated with a 3-fold increased inpa-
tient and up to 50% 3-month mortality.1 In recent years, in-
terest has risen regarding the use of a variety of endovascular
strategies in selected patients with MPE involving catheter-
based techniques.5e7 UCDT, which uses low intensity high
ultrasonic energy, represents a novel treatment strategy. The
acoustic streaming energy dissociates the fibrin strands and
increases the fibrin porosity without causing distal fragmen-
tation or embolization, allowing the utilization of intra-
pulmonary thrombolytic agents at lower doses and infusion
rates, achieving a more complete thrombolysis.2,8
Two recent clinical studies (one case series and one
comparative study) analyzed the therapeutic outcomes of a
catheter-directed thrombolysis versus UCDT-based strategy
for MPE, demonstrating acceptable effectiveness, thrombus
burden resolution, and improvement in hemodynamic pa-
rameters.6,7 Lin et al noted an overall reduction in hemor-
rhagic complications in the group using the UCDT strategy.7
Engelhardt et al9 studied retrospectively 24 patients, with
19 with submassive and 5 with massive PE, by using UCDT,
they found a significant reversal in RV dysfunction by per-
forming pre and post intervention by CTA imaging right to left
ventricular dimension ratio (RV/LV ratio) (p  0.001), and
without reporting any significant or serious hemorrhagic
complications upon discharge from the hospital.
Kuo et al10 performed a meta-analysis of 594 patients with
MPE treated with modern catheter-directed therapeutic in-
terventions, clinical success was achieved in 86.5%, with
success being defined as stabilization of hemodynamics, res-
olution of hypoxemia, and survival upon hospital discharge.
Also, when injected locally, the required dose of thrombolytics
is likely to be lower when compared with systemic throm-
bolysis, demonstrated a lower risk for significant hemorrhagic
complications.10 Indeed, the rate of major complications (e.g.
pulmonary hemorrhage from pulmonary artery rupture or
dissection) from modern catheter-directed interventions has
proven to be only 2.4%.10,11 Interestingly, this meta-analysis
clearly demonstrated that the pool frequency of clinical suc-
cess was higher when patients received UCDT strategies
compared with percutaneous mechanical thrombectomy
(PMT) without local thrombolysis (91.2% vs 86.3%;
p ¼ 0.01).10,11
Recently, the ULTIMA trial (Ultrasound-accelerated
Thrombolysis of Pulmonary Embolism) was just completed
and the results were presented. In this prospective double-
blind study, 59 patients were prospectively randomized toreceive anticoagulation or UCDT via the Ekosonic endovas-
cular system (EKOS). Within 24 h of therapy, patients treated
with UCDT strategy demonstrated statistically significance
reduction in RV enlargement (improvement of the RV/LV ratio,
23% p < 0.001) with no adverse events from the invasive pro-
cedure.12 Theongoing single-arm,multicenter SEATTLE-II trial
is currently looking in to the efficacy and safety of UCDT using
the EKOS catheter, with a primary end-point of decreasing
RV/LV ratio measured by CTA post-48 h after UCDT catheter-
based strategy in 150 patients with MPE and submassive PE.134. Conclusions
The best current emerging evidence suggests that UCDT rep-
resents an attractive and promising endovascular technique
for the treatment of MPE as an early and first-line of therapy in
order to achieve rapid clot debulking. The use of these
particular endovascular techniques appear to be a promising
option in order to reduce the incidence of chronic thrombo-
embolic pulmonary hypertension, while avoiding the hemor-
rhagic risks of full-dose systemic thrombolysis.
Further research on UCDT focusing on MPE and sub-
massive PE is needed in order to refine existing protocols and
to evaluate long-term outcomes. Rapid and efficient risk
stratification in the setting of acute.
Despite cumulative evidence regarding the use of UCDT,
there are many limitations regarding this therapeutic mo-
dality, including the absence of standardized protocols and
the lack of experienced operators. Ongoing prospective ran-
domized controlled trials will help standardize therapeutic
protocols and guidelines for its use in the setting of massive
and submassive PE.Conflicts of interest
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21.08.13.ObituaryDr. H.S. Rissam, Director, Clinical Cardiac Sciences &
Senior Interventional Cardiologist at Max Heart & Vascular
Institute, New Delhi expired recently. He did his cardiology at
PGIMER, Chandigarh. He had a particular interest in preven-
tive cardiology.
Dr. H.S. Rissamwas widely known and was active in many
fields of cardiology including the activities of Cardiological
Society of India. The Government of India awarded him
Padmashree in the year 2006. He had a special interest in
writing and has authored “Scalpel” a book on medical mys-
tery. A very affable person, we will all miss him badly in car-
diology circles.
The CSI Executives joins me in expressing deepest condo-
lences to the bereaved family.
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